plozasiran
EMA backs plozasiran for rare lipid disorder with high pancreatitis risk
April 27, 2026Research and Development The European Medicines Agency (EMA), plozasiran
The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Redemplo (plozasiran) to treat adults with familial chylomicronaemia …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
